COMPARISON OF CELL LYSIS MEDIATED BY LFB-R603 (UBLITUXIMAB) WITH THAT MEDIATED BY OFATUMUMAB AGAINST CELLS EXPRESSING LOW LEVELS OF CD20

Anne Bellon 1, Alain Sadoun 1, Karine Grivel 2, Maxime Moulard 1, Frédéric Brune 1, Jean-François Prost 1, Margarita Salcedo 1

1 LFB BIOTECHNOLOGIES, Les Ulis, France; 2 BioCytex, Marseille, France

53rd ASH Annual Meeting, San Diego USA, December 10-13, 2011

Abstract No. 3913

In the study reported here, we further investigated the B-cell lysis activity of LFB-R603 (ublituximab), a novel anti-CD20 monoclonal antibody that targets the CD20 antigen on the surface of B-cells, and ofatumumab from PMBC from CLL patients. In terms of CDC-mediated lysis, observed higher CDC activity of ofatumumab when compared with LFB-R603 on several cell lines expressing high CD20 levels (data not shown).

Perspectives

We plan to confirm, in the next clinical study that LFB-R603 is able to induce a killing of low-CD20 expressing target cells than ofatumumab and rituximab in CLL patients.

\( \text{COMPARISON OF CELL LYSIS MEDIATED BY LFB-R603 (UBLITUXIMAB) WITH THAT MEDIATED BY OFATUMUMAB AGAINST CELLS EXPRESSING LOW LEVELS OF CD20} \)

\( \text{Anne Bellon 1, Alain Sadoun 1, Karine Grivel 2, Maxime Moulard 1, Frédéric Brune 1, Jean-François Prost 1, Margarita Salcedo 1} \)

\( \text{1 LFB BIOTECHNOLOGIES, Les Ulis, France; 2 BioCytex, Marseille, France} \)

\( \text{53rd ASH Annual Meeting, San Diego USA, December 10-13, 2011} \)

\( \text{Abstract No. 3913} \)

In the study reported here, we further investigated the B-cell lysis activity of LFB-R603 (ublituximab), a novel anti-CD20 monoclonal antibody that targets the CD20 antigen on the surface of B-cells, and ofatumumab from PMBC from CLL patients. In terms of CDC-mediated lysis, observed higher CDC activity of ofatumumab when compared with LFB-R603 on several cell lines expressing high CD20 levels (data not shown).

\( \text{Perspectives} \)

We plan to confirm, in the next clinical study that LFB-R603 is able to induce a killing of low-CD20 expressing target cells than ofatumumab and rituximab in CLL patients.